GlassScriptPhysician profile
Baby Than
NPI 1033371554
$7,688.46
in general payments reported to CMS, 2019-2025
31 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $408 · 2021: $908 · 2022: $1,059 · 2023: $1,368 · 2024: $1,242 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,107.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $998.51 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $953.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $811.79 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $797.92 | 2019-2025 | |
| Lilly USA, LLC | $782.71 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.99 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $245.07 | 2019-2022 | |
| Biosense Webster, INC. | $217.81 | 2024-2025 | Carto 3 |
| Abbott Laboratories | $216.43 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $160.38 | 2019-2020 | |
| Mylan Specialty L.P. | $108.94 | 2019-2022 | |
| Boston Scientific Corporation | $81.48 | 2024 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company LTD. | $74.43 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $73.05 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $58.81 | 2019 | |
| Abbvie INC. | $55.06 | 2022-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $49.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.15 | 2019 | |
| Dexcom, INC. | $40.81 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.37 | 2020 | |
| Celgene Corporation | $30.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.12 | 2019 | |
| Ucb, INC. | $24.29 | 2019 | |
| Eisai INC. | $20.06 | 2019 | |
| Genentech USA, INC. | $16.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2021 | |
| Shire North American Group INC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baby Than listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.